HIV has become a chronic disease since widespread of combined antiretroviral therapy (cART). Understanding the influence of therapeutic and preventive interventions on health-related quality of life (HRQoL) of people living with HIV and AIDS (PLWHA) is important. Information about health state utilities and HRQoL in PLWHA after the introduction of cART is limited, especially in Germany. The study aims to estimate and describe health state utilities and HRQoL in PLWHA in Germany and explore the effects of patient characteristics, clinical and treatment factors. Utilities and HRQoL in PLWHA in Germany were measured with the generic EQ-5D-3L questionnaire. Health state utilities were calculated based on the EQ-5D descriptive system using the German EQ-5D-3L time trade-off (TTO) value set. HRQoL was calculated based on the EQ visual analogue scale (EQ-VAS). Extensive descriptive analyses were performed to represent utility values for different groups of the patients. Generalized linear models (GLMs) with beta-inflated distributions were used to determine patient characteristics and clinical factors that influence TTO utilities and VAS scores. 1056 PLWHA completed the EQ-5D-3L questionnaires at the beginning of the study. The mean TTO utility value is 0.912 (SD ± 0.154), and the mean VAS HRQoL is 84.32 (SD ± 18.55). “Anxiety/depression” and “pain/physical discomfort” are the most affected dimensions. A longer period of living with HIV, a lower CD4-cell count, having symptomatic HIV or AIDS and an increased number of changes in therapy are associated with decreased utilities and a lower probability of having HRQoL of perfect health. No significant effect of duration of regimen was found. Depression significantly decreases TTO utility values. Higher education, full-time employment and female gender are associated with higher utilities. The resulted EQ-VAS values for PLWHA in Germany are comparable with EQ-VAS estimates for the general population. The obtained estimates can be used as inputs for health economic evaluations of HIV-interventions. Addressing anxiety and depression may reduce the quality of life impairment in PLWHA. Impact of comorbidities needs further investigation.

自广泛使用抗逆转录病毒疗法（cART）以来，HIV已成为一种慢性疾病。了解治疗性和预防性干预措施对艾滋病毒和艾滋病患者（PLWHA）的健康相关生活质量（HRQoL）的影响非常重要。引入cART后，有关PLWHA中的健康状态实用程序和HRQoL的信息非常有限，尤其是在德国。该研究旨在评估和描述德国PLWHA的健康状况效用和HRQoL，并探讨患者特征，临床和治疗因素的影响。使用通用的EQ-5D-3L问卷对德国PLWHA的公用事业和HRQoL进行了测量。使用德国EQ-5D-3L时间权衡（TTO）值集，基于EQ-5D描述性系统计算了健康状态效用。HRQoL是根据EQ视觉模拟量表（EQ-VAS）计算的。进行了广泛的描述性分析，以代表不同组患者的效用值。使用具有β膨胀分布的广义线性模型（GLM）来确定影响TTO效用和VAS分数的患者特征和临床因素。1056 PLWHA在研究开始时完成了EQ-5D-3L问卷。平均TTO效用值为0.912（SD±0.154），平均VAS HRQoL为84.32（SD±18.55）。“焦虑/抑郁”和“疼痛/身体不适”是受影响最大的方面。感染艾滋病毒的时间更长，CD4细胞数量较少，有症状的艾滋病毒或艾滋病以及治疗方法的改变数量增加，与效用降低和拥有完美健康的HRQoL的可能性降低相关。没有发现疗程持续时间的显着影响。抑郁会大大降低TTO效用值。高等教育，全职工作和女性性别与更高的公用事业息息相关。在德国，所得的PLWHA的EQ-VAS值与一般人群的EQ-VAS估计值相当。获得的估计值可以用作对HIV干预措施进行健康经济评估的输入。解决焦虑症和抑郁症可能会降低PLWHA的生活质量。合并症的影响有待进一步调查。在德国，所得的PLWHA的EQ-VAS值与一般人群的EQ-VAS估计值相当。获得的估计值可以用作对HIV干预措施进行健康经济评估的输入。解决焦虑症和抑郁症可能会降低PLWHA的生活质量。合并症的影响有待进一步调查。在德国，所得的PLWHA的EQ-VAS值与一般人群的EQ-VAS估计值相当。获得的估计值可以用作对HIV干预措施进行健康经济评估的输入。解决焦虑症和抑郁症可能会降低PLWHA的生活质量。合并症的影响有待进一步调查。